CSL agreed to pay $355 million upfront to co-develop Alentis Therapeutics’ kidney and liver anti-fibrosis program, with potential future payments of up to $1.2 billion. The deal adds another late-stage fibrosis-related asset to CSL’s pipeline and expands its footprint in organ fibrosis beyond prior platforms. For Alentis, the financing and development commitment provides additional runway and shared clinical execution capacity for a program aimed at fibrotic disease mechanisms affecting both renal and hepatic tissues. CSL’s involvement also signals continued payer and investor appetite for therapies targeting fibrosis, where unmet need remains high and endpoints are increasingly measured with imaging and biomarker strategy. The collaboration is expected to support joint development activities across premarket studies and translational work to define efficacy in target populations, while also building commercial optionality tied to trial outcomes.